Astrazeneca (AZN) Non-Current Assets (2009 - 2026)

Astrazeneca's Non-Current Assets history runs 18 years deep, the most recent figure standing at $84.4 billion for Q1 2026.

• In Q1 2026, Non-Current Assets rose 5.35% year-over-year to $84.4 billion; the TTM figure through Mar 2026 stood at $84.4 billion (up 5.35% YoY), while the FY2025 annual figure was $85.4 billion, up 21.47% from the prior year.
• Non-Current Assets was $84.4 billion for Q1 2026 at Astrazeneca, down from $85.4 billion in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $85.4 billion in Q4 2025 to a low of $68.9 billion in Q4 2022.
• Historically, Non-Current Assets has averaged $77.1 billion across 5 years, with a median of $76.7 billion in 2024.
• Biggest YoY gain for Non-Current Assets was 112.7% in 2022; the steepest drop was 8.16% in 2022.
• A 5-year view of Non-Current Assets shows it stood at $68.9 billion in 2022, then increased by 0.15% to $69.0 billion in 2023, then gained by 1.88% to $70.3 billion in 2024, then grew by 21.47% to $85.4 billion in 2025, then decreased by 1.11% to $84.4 billion in 2026.
• The last three Non-Current Assets figures came in at $84.4 billion (Q1 2026), $85.4 billion (Q4 2025), and $84.5 billion (Q3 2025), per Business Quant data.